Ubs Asset Management Americas Inc Prothena Corp Public LTD CO Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 139,284 shares of PRTA stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139,284

Previous 381,652 63.5%

Holding current value

$1.05 Million

Previous $4.72 Million 82.11%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$4.58 - $12.14 $1.11 Million - $2.94 Million	-242,368 Reduced 63.5%	139,284 $845,000
Q1 2025 May 19, 2025	BUY	$12.38 - $16.04 $1,782 - $2,309	144 Added 0.04%	381,652 $4.72 Million
Q4 2024 Feb 14, 2025	SELL	$11.95 - $18.35 $1.74 Million - $2.67 Million	-145,240 Reduced 27.57%	381,508 $5.28 Million
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $8.09 Million - $12 Million	483,673 Added 1122.86%	526,748 $8.81 Million
Q2 2024 Aug 13, 2024	SELL	$19.54 - $26.15 $6.49 Million - $8.68 Million	-332,090 Reduced 88.52%	43,075 $889,000
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $2.06 Million - $3.39 Million	83,298 Added 28.54%	375,165 $9.29 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $834,244 - $1.35 Million	25,820 Added 9.71%	291,867 $10.6 Million
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $1.88 Million - $2.81 Million	39,845 Added 17.61%	266,047 $12.8 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $101,737 - $126,212	-2,166 Reduced 0.95%	226,202 $11 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $762,116 - $951,730	-14,642 Reduced 6.03%	228,368 $13.8 Million
Q2 2022 Aug 12, 2022	SELL	$22.73 - $39.98 $385,591 - $678,220	-16,964 Reduced 6.53%	243,010 $6.6 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $835,841 - $1.45 Million	-19,849 Reduced 7.09%	259,974 $12.8 Million
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $5.9 Million - $9.65 Million	-122,345 Reduced 30.42%	279,823 $19.9 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $1.07 Million - $2.86 Million	49,641 Added 14.08%	402,168 $20.7 Million
Q1 2021 May 14, 2021	BUY	$11.0 - $28.24 $3.48 Million - $8.94 Million	316,420 Added 876.34%	352,527 $8.86 Million
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $59,826 - $78,287	-6,258 Reduced 14.77%	36,107 $377,000
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $83,301 - $174,226	-11,048 Reduced 20.68%	42,365 $453,000
Q4 2019 Feb 14, 2020	BUY	$7.48 - $17.01 $143,212 - $325,673	19,146 Added 55.87%	53,413 $845,000
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $23,784 - $36,073	3,452 Added 11.2%	34,267 $268,000
Q2 2019 Aug 15, 2019	BUY	$8.85 - $12.49 $30,930 - $43,652	3,495 Added 12.79%	30,815 $0
Q1 2019 May 14, 2019	BUY	$10.32 - $14.49 $127,142 - $178,516	12,320 Added 82.13%	27,320 $0
Q2 2018 Aug 14, 2018	BUY	$10.99 - $44.21 $164,322 - $661,027	14,952 Added 31150.0%	15,000 $0
Q3 2017 Nov 13, 2017	BUY	$53.83 - $67.75 $2,583 - $3,252	48	48 $0

Others Institutions Holding PRTA

# of Institutions

219

Shares Held

34.1M

Call Options Held

890K

Put Options Held

791K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $354M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Prothena Corp Public LTD CO Transaction History